ArticleBMC biology2025
NeuroScale: evolutional scale-based protein language models enable prediction of neuropeptides.
Article in BMC biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Hyperhomocysteinemia in chronic schizophrenia: prevalence, clinical correlates, and paradoxical associations with symptom severity.European archives of psychiatry and clinical neuroscience · 2026Article
- A Multi-Omics Integration Framework with Automated Machine Learning Identifies Peripheral Immune-Coagulation Biomarkers for Schizophrenia Risk Stratification.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundNeuropeptides (NPs) are critical signaling molecules involved in various physiological and behavioral processes, including development, metabolism, and memory. They function within both the nervous and endocrine systems and have emerged as promising therapeutic targets for a range of diseases. Despite their significance, the accurate identification of NPs remains a challenge, necessitating the development of more effective computational approaches.
resultsIn this study, we introduce NeuroScale, a multi-channel neural network model leveraging evolutionary scale modeling (ESM) for the precise prediction of NPs. By integrating the GoogLeNet framework, NeuroScale effectively captures multi-scale NP features, enabling robust and accurate classification. Extensive benchmarking demonstrates its superior performance, consistently achieving an area under the receiver operating characteristic curve (AUC) exceeding 0.97. Additionally, we systematically analyzed the impact of protein sequence similarity thresholds and multi-scale sequence lengths on model performance, further validating NeuroScale's robustness and generalizability.
conclusionsNeuroScale represents a significant advancement in neuropeptide prediction, offering both high accuracy and adaptability to diverse sequence characteristics. Its ability to generalize across different sequence similarity thresholds and lengths underscores its potential as a reliable tool for neuropeptide discovery and peptide-based drug development. By providing a scalable and efficient deep learning framework, NeuroScale paves the way for future research in neuropeptide function, disease mechanisms, and therapeutic applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.